Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.48 |
| ▸ | HRH2 | P25021 | 4/20 | 0.48 |
| ▸ | HRH1 | P35367 | 4/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059171 | 1.00 | HRH3 (0.48) | HRH3HRH2HRH1CYP2D6CYP2C19 | |
| SCHEMBL22890917 | 0.90 | HTR1A (0.57) | HRH3HRH2HRH1CYP2D6CYP2C19 | |
| SCHEMBL22861390 | 0.90 | HTR1A (0.57) | HRH3HRH2HRH1CYP2D6CYP2C19 | |
| SCHEMBL21000416 | 0.90 | HTR1A (0.57) | HRH3HRH2HRH1CYP2D6CYP2C19 | |
| SCHEMBL21738355 | 0.89 | HRH3 (0.46) | HRH3HRH2HRH1CYP2D6CYP2C19 | |
| SCHEMBL21000316 | 0.87 | GLB1 (0.42) | HRH3HRH2HRH1CYP2D6CYP2C19 | |
| SCHEMBL12717290 | 0.84 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL9921265 | 0.84 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL13552419 | 0.84 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL22281941 | 0.83 | CYP2D6 (0.48) | HRH3HRH2HRH1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207173-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ZC3HAV1, NXF1, ZC3HAV1L | HRH3 1057/4885HRH2 756/4885HRH1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.